查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477347

轉染技術市場 - 全球產業規模、佔有率、趨勢、機會和預測，按轉染方法、產品、應用、技術、地區和競爭細分，2019-2029F

Transfection Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Transfection Method, By Product, By Applications, By Technology, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球轉染技術市場價值為 12.3 億美元，預計到 2029 年預測期內將以 9.61% 的複合年成長率實現令人印象深刻的成長。

市場概況
預測期 2025-2029
2023 年市場規模 12.3億美元
2029 年市場規模 21.2億美元
2024-2029 年複合年成長率 9.61%
成長最快的細分市場 脂轉染
最大的市場 北美洲

轉染技術是指將外源性核酸（例如DNA、RNA或寡核苷酸）引入真核細胞的一組方法和技術。轉染的主要目標是操縱基因表現、研究細胞過程或為各種生物醫學和研究應用提供治療劑。轉染技術廣泛應用於研究基因功能、蛋白質表現、訊號傳導路徑和細胞過程的基礎研究。研究人員操縱基因表現模式來闡明基因功能、識別調控元件並探索疾病機制。轉染技術透過實現化合物庫的高通量篩選、標靶驗證研究和功能基因組學方法，在藥物發現和開發中發揮至關重要的作用。轉染細胞可作為研究藥物功效、毒性和作用機制的模型。轉染技術對於旨在治療遺傳性疾病、癌症和其他疾病的基因治療應用至關重要。研究人員將治療基因或 RNA 分子傳遞到目標細胞中，以糾正遺傳缺陷、調節基因表現或誘導對腫瘤的免疫反應。

CRISPR-Cas9 等基因編輯技術的快速進步，以及對基因療法應用日益成長的興趣，推動了對將治療性核酸遞送至目標細胞的轉染技術的需求。細胞生物學、分子生物學和相關領域的持續研究推動了對有效轉染方法的需求，以研究基因功能、蛋白質表現、訊號傳導途徑和細胞訊號傳導機制。全球生物技術和製藥行業的擴張推動了藥物發現、標靶驗證、高通量篩選和生物製造流程對轉染技術的需求。轉染技術的持續技術進步和產品創新，包括新型轉染試劑、遞送系統和自動化平台的開發，透過提高轉染效率、特異性和易用性來推動市場成長。人們對基於 RNA 的療法（包括 mRNA 疫苗、RNA 干擾 (RNAi) 療法和反義寡核苷酸療法）的興趣日益濃厚，推動了對將 RNA 分子遞送至目標細胞的有效轉染方法的需求。

主要市場促進因素

基因編輯和治療的進展

擴大細胞生物學和分子生物學研究

生物技術和製藥業的擴張

主要市場挑戰

細胞毒性和細胞活力

免疫反應和炎症

主要市場趨勢

關注非病毒轉染方法

細分市場洞察

轉染方法見解

技術洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依轉染方法（共轉染、電穿孔、陽離子脂質轉染、脂轉染、核轉染、體內轉染）
    • 依產品（試劑、儀器、其他）
    • 按應用（病毒生產、蛋白質生產、基因沉默、幹細胞重編程和分化、穩定細胞株生成、治療遞送、生物醫學研究、蛋白質生產等）
    • 依技術分類（物理轉染、生化轉染、病毒載體轉染）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過轉染方法
    • 按產品分類
    • 按申請
    • 依技術
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過轉染方法
    • 按產品分類
    • 按申請
    • 依技術
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過轉染方法
    • 按產品分類
    • 按申請
    • 依技術
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過轉染方法
    • 按產品分類
    • 按申請
    • 依技術
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲轉染技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過轉染方法
    • 按產品分類
    • 按申請
    • 依技術
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Promega Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Roche Molecular Systems, Inc.
  • QIAGEN NV
  • Inovio Pharmaceuticals
  • Mirus Bio LLC
  • Takara Bio Inc.
  • SignaGen Laboratories
  • MaxCyte, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23801

Global Transfection Technologies Market was valued at USD 1.23 billion in 2023 and expected to experience impressive growth in the forecast period at a CAGR of 9.61% through 2029.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.23 Billion
Market Size 2029USD 2.12 Billion
CAGR 2024-20299.61%
Fastest Growing SegmentLipofection
Largest MarketNorth America

Transfection technologies refer to a set of methods and techniques used to introduce foreign nucleic acids, such as DNA, RNA, or oligonucleotides, into eukaryotic cells. The primary goal of transfection is to manipulate gene expression, study cellular processes, or deliver therapeutic agents for various biomedical and research applications. Transfection technologies are widely used in basic research to study gene function, protein expression, signal transduction pathways, and cellular processes. Researchers manipulate gene expression patterns to elucidate gene function, identify regulatory elements, and explore disease mechanisms. Transfection technologies play a crucial role in drug discovery and development by enabling high-throughput screening of compound libraries, target validation studies, and functional genomics approaches. Transfected cells serve as models for studying drug efficacy, toxicity, and mechanisms of action. Transfection technologies are essential for gene therapy applications aimed at treating genetic disorders, cancer, and other diseases. Researchers deliver therapeutic genes or RNA molecules into target cells to correct genetic defects, modulate gene expression, or induce immune responses against tumors.

The rapid advancements in gene editing technologies, such as CRISPR-Cas9, and the growing interest in gene therapy applications fuel the demand for transfection technologies for delivering therapeutic nucleic acids into target cells. Ongoing research in cell biology, molecular biology, and related fields drives the need for efficient transfection methods for studying gene function, protein expression, signal transduction pathways, and cell signaling mechanisms. The expansion of the biotechnology and pharmaceutical industries worldwide drives the demand for transfection technologies for drug discovery, target validation, high-throughput screening, and biomanufacturing processes. Continuous technological advancements and product innovations in transfection technologies, including the development of novel transfection reagents, delivery systems, and automated platforms, drive market growth by improving transfection efficiency, specificity, and ease of use. The growing interest in RNA-based therapeutics, including mRNA vaccines, RNA interference (RNAi) therapies, and antisense oligonucleotide therapies, fuels the demand for efficient transfection methods for delivering RNA molecules into target cells.

Key Market Drivers

Advancements in Gene Editing and Therapy

CRISPR-Cas9 is a revolutionary gene-editing tool that allows precise modification of DNA sequences within the genome. It enables researchers to edit genes by cutting DNA at specific locations and introducing desired changes. CRISPR-Cas9 has significantly simplified and accelerated the process of genome editing, making it widely accessible to researchers worldwide. Since its discovery, researchers have developed various CRISPR variants, including base editors, prime editors, and CRISPR interference (CRISPRi) systems. These advanced tools offer enhanced precision, efficiency, and versatility in genome editing, expanding the scope of applications in basic research and therapeutic development. Gene therapy involves delivering therapeutic genes into patient cells to treat genetic disorders or diseases. Recent breakthroughs in gene therapy have led to the development of FDA-approved treatments for inherited retinal disorders, spinal muscular atrophy, and certain types of leukemia. These successes highlight the potential of gene therapy as a promising treatment modality. Gene editing technologies, such as CRISPR, are being used to engineer immune cells, such as T cells, to enhance their ability to recognize and kill cancer cells. Chimeric antigen receptor (CAR) T-cell therapy, which involves modifying patient T cells to express synthetic receptors targeting tumor antigens, has shown remarkable efficacy in treating certain types of blood cancers.

One of the key challenges in gene editing and therapy is delivering therapeutic genes or editing tools into target cells effectively and safely. Advances in viral and non-viral delivery systems, nanoparticle-based carriers, and exosome-mediated delivery methods are improving the efficiency, specificity, and safety of gene delivery in preclinical and clinical settings. Gene editing technologies enable personalized medicine approaches by targeting specific genetic mutations associated with individual patients' diseases. This precision allows for tailored treatments that address the underlying genetic causes of diseases, potentially improving therapeutic outcomes and reducing adverse effects. As gene editing technologies advance, ethical and regulatory considerations surrounding their use become increasingly important. The scientific community and regulatory agencies are actively engaged in discussions regarding the ethical implications, safety concerns, and regulatory oversight of gene editing applications, particularly those involving germline editing and heritable genetic modifications. This factor will help in the development of the Global Transfection Technologies Market.

Expanding Research in Cell Biology and Molecular Biology

Researchers use transfection technologies to introduce specific genes or gene fragments into cells to study their functions. By modulating gene expression levels or introducing mutations, scientists can elucidate the roles of individual genes in cellular processes, development, and disease. Transfection techniques are essential for expressing recombinant proteins in cultured cells. Researchers use these proteins to study protein-protein interactions, protein localization, post-translational modifications, and other aspects of protein function and regulation. Transfection technologies enable researchers to manipulate signaling pathways within cells by introducing signaling molecules, inhibitors, or activators. This allows for the investigation of signal transduction mechanisms, cellular responses to extracellular stimuli, and the identification of potential drug targets. Transfection methods are used to introduce fluorescent or luminescent reporter genes into cells for imaging and localization studies. By visualizing the subcellular localization of proteins or tracking dynamic changes in gene expression over time, researchers gain insights into cellular dynamics and regulatory mechanisms.

Transfection technologies play a crucial role in drug discovery by enabling high-throughput screening of compound libraries and target validation studies. Transfected cells can be used to assess drug efficacy, toxicity, and mechanism of action, accelerating the drug discovery process. Transfection methods are utilized in stem cell research for genetic manipulation, reprogramming, and differentiation of stem cells into specialized cell types. Researchers use transfection technologies to introduce transcription factors, growth factors, or small molecules that induce specific cellular fates or phenotypes. Transfection techniques are employed in functional genomics studies to silence or overexpress specific genes of interest using RNA interference (RNAi) or expression plasmids, respectively. These approaches enable the systematic analysis of gene function and the identification of genes involved in biological processes and disease pathways. Transfection technologies are utilized in cancer research to study oncogenes, tumor suppressor genes, and molecular pathways involved in cancer progression and metastasis. Transfected cells are also used to investigate the mechanisms of action of anticancer drugs and to develop novel therapeutic strategies, such as gene therapy and immunotherapy. This factor will pace up the demand of the Global Transfection Technologies Market.

Expansion of Biotechnology and Pharmaceutical Industries

Biotechnology companies utilize transfection technologies to produce recombinant proteins, monoclonal antibodies, vaccines, and other biologics. Transfection methods enable the efficient transfer of genetic material into host cells, allowing them to express therapeutic proteins or antigens for use in drug development and manufacturing. The biotechnology and pharmaceutical industries are increasingly investing in gene therapy and genome editing technologies to develop novel treatments for genetic disorders, cancer, and other diseases. Transfection technologies play a crucial role in delivering therapeutic genes or gene-editing tools into target cells for gene correction, gene silencing, or gene expression modulation. Pharmaceutical companies rely on transfection technologies for high-throughput screening of compound libraries and target validation studies. Transfected cells expressing target proteins or RNA molecules can be used to identify potential drug candidates, assess drug efficacy, and elucidate molecular mechanisms underlying disease pathways. Transfection methods are used to create cell-based assays and disease models for drug screening and preclinical testing. By introducing specific genes or genetic modifications into cultured cells, researchers can mimic disease conditions, study disease mechanisms, and evaluate the effects of potential therapeutics in vitro.

The advent of personalized medicine has led to increased demand for transfection technologies in biomarker discovery and patient stratification studies. Transfected cells expressing disease-associated genes or biomarkers can be used to identify patient subpopulations that are likely to respond to specific treatments, enabling more targeted and personalized therapeutic interventions. Transfection methods are employed in vaccine development to produce viral vectors or recombinant antigens for vaccine formulations. Transfected cells serve as platforms for the expression and production of vaccine candidates, facilitating the development and scale-up of vaccines against infectious diseases and emerging pathogens. With the growing interest in cell and gene therapies, there is an increasing need for scalable and reproducible transfection technologies for manufacturing clinical-grade cell therapy products. Transfection methods are used to genetically modify patient-derived cells ex vivo before reinfusion, enabling personalized cell therapies for cancer, autoimmune disorders, and regenerative medicine applications. This factor will accelerate the demand of the Global Transfection Technologies Market.

Key Market Challenges

Cytotoxicity and Cell Viability

Certain transfection methods, particularly those involving physical means like electroporation or chemical means like some lipid-based transfection reagents, can cause cellular damage. This damage may result from membrane disruption, alterations in cell physiology, or induction of stress responses, leading to reduced cell viability. Transfection-induced cellular damage can trigger inflammatory responses, including the release of pro-inflammatory cytokines and activation of immune cells. These inflammatory reactions may further compromise cell viability and affect experimental outcomes, particularly in sensitive cell types or in vivo models. Some transfection methods result in transient expression of transfected genes or transient alterations in cellular physiology. During the transient phase, cells may undergo metabolic changes or experience stress responses that impact viability and function, limiting the duration and reliability of experimental results. The extent of cytotoxicity and its impact on cell viability often depends on factors such as transfection reagent concentration, transfection protocol parameters, and cell type. Finding the optimal balance between transfection efficiency and cell viability requires careful optimization and validation of transfection conditions. Different cell types exhibit varying sensitivities to transfection-induced cytotoxicity. Primary cells, stem cells, and certain specialized cell lines may be particularly susceptible to damage during transfection procedures, necessitating the use of gentler or cell type-specific transfection methods to preserve viability and functionality. Reduced cell viability and increased cytotoxicity can adversely affect downstream applications, including cell proliferation assays, functional studies, and long-term culture experiments. Contaminating factors introduced during transfection or associated with cytotoxicity may confound experimental results and compromise data interpretation.

Immune Response and Inflammation

Many transfection methods rely on the use of viral vectors, lipid-based nanoparticles, or other delivery vehicles to transport nucleic acids into target cells. These delivery vehicles can trigger immune responses, leading to inflammation and potential adverse effects in vivo. The introduction of foreign nucleic acids into cells can activate innate immune pathways, such as Toll-like receptor (TLR) signaling and the interferon response. These immune responses can lead to the production of pro-inflammatory cytokines and chemokines, causing inflammation and cellular stress. In some cases, transfection-mediated expression of exogenous proteins or antigens may elicit adaptive immune responses, including the production of antibodies or activation of cytotoxic T cells. These immune reactions can limit the duration of transgene expression and compromise the efficacy of transfection-based therapies. Persistent inflammation resulting from immune responses to transfection agents or exogenous nucleic acids can lead to tissue damage and toxicity, particularly in organs or tissues with high metabolic activity or immune cell infiltration. Immune responses triggered by transfection-mediated gene expression or delivery can have off-target effects, impacting neighboring cells, tissues, or organs. The nonspecific activation of immune cells or inflammatory pathways may result in unintended consequences and systemic side effects. In the context of clinical applications, such as gene therapy or nucleic acid-based vaccines, minimizing immune responses and inflammation is crucial for ensuring the safety and efficacy of transfection technologies. Immune-mediated adverse events can compromise patient outcomes and hinder the development of transfection-based therapeutics.

Key Market Trends

Focus on Non-viral Transfection Methods

Non-viral transfection methods are generally considered safer than viral vectors, which can elicit immune responses and potentially integrate into the host genome. Non-viral methods typically involve the use of synthetic or natural carriers, reducing the risk of immunogenicity and genotoxicity. Viral vectors used in gene therapy can integrate into the host genome, potentially causing insertional mutagenesis and oncogenesis. Non-viral methods, such as lipid-based or polymer-based transfection reagents, do not integrate into the genome, minimizing the risk of genetic alterations. Non-viral transfection methods offer greater flexibility and versatility in terms of nucleic acid cargo, cell types, and experimental conditions. Researchers can easily modify and optimize non-viral transfection protocols to suit specific research or therapeutic applications without the constraints associated with viral vectors. Non-viral transfection reagents and carriers are typically easier and more cost-effective to manufacture compared to viral vectors. The scalability of non-viral methods allows for large-scale production of transfection reagents, facilitating their widespread use in research and clinical settings. Non-viral transfection methods are compatible with a wide range of cell types, including primary cells, stem cells, and hard-to-transfect cell lines. This broad applicability makes non-viral methods suitable for diverse research areas and therapeutic applications. Non-viral transfection reagents and carriers generally exhibit minimal immunogenicity, reducing the risk of immune responses and inflammatory reactions. This feature is particularly important for in vivo applications, where immune reactions can compromise therapeutic efficacy and safety.

Segmental Insights

Transfection Method Insights

Based on the transfection method, the Cationic Lipid Transfection segment is projected to experience rapid growth in the Global Transfection Technologies Market during the forecast period. Cationic lipid-based transfection methods have demonstrated high transfection efficiency in delivering nucleic acids, such as DNA and RNA, into a wide range of cell types. These lipid-based formulations form complexes with nucleic acids, facilitating their uptake by cells and subsequent gene expression. Cationic lipid transfection is suitable for transfecting various types of cells, including primary cells, stem cells, and hard-to-transfect cell lines. The versatility of cationic lipid-based transfection makes it applicable across diverse research areas and therapeutic applications. Compared to some other transfection methods, cationic lipid-based transfection is generally associated with lower cytotoxicity. The lipid-based formulations are designed to minimize cellular stress and maintain high cell viability, making them suitable for sensitive cell types and long-term experiments. Cationic lipid-based transfection methods are compatible with different types of nucleic acids, including plasmid DNA, mRNA, siRNA, and miRNA. This flexibility allows researchers and clinicians to use cationic lipid transfection for a wide range of applications, from gene overexpression to gene silencing and gene editing. Cationic lipid-based transfection protocols are generally straightforward and easy to optimize for specific cell types and experimental conditions. This ease of use makes cationic lipid transfection accessible to researchers with varying levels of expertise in molecular biology and cell culture techniques. Cationic lipid-based transfection methods can be scaled up for high-throughput applications, making them suitable for large-scale screening studies, drug discovery efforts, and biomanufacturing processes.

Technology Insights

Based on the technology, Biochemical Based Transfection segment is projected to experience rapid growth in the Global Transfection Technologies Market during the forecast period. Biochemical-based transfection methods typically involve the use of lipid-based or polymer-based transfection reagents. These reagents are designed to encapsulate nucleic acids and facilitate their delivery into cells. Compared to viral-based transfection methods, biochemical-based approaches are generally safer and less immunogenic, making them attractive for various applications, including gene therapy and research. Biochemical-based transfection methods are versatile and can be used to transfect a wide range of cell types, including primary cells, stem cells, and difficult-to-transfect cells. This versatility makes biochemical-based transfection methods suitable for various research and therapeutic applications. Biochemical-based transfection reagents are often user-friendly and easy to use, requiring minimal optimization for different cell types. Additionally, biochemical-based transfection methods can be scaled up for high-throughput applications, making them suitable for large-scale research and production purposes. Advances in biochemical-based transfection reagents and protocols have led to significant improvements in transfection efficiency. New formulations and delivery systems have been developed to enhance the delivery of nucleic acids into target cells, resulting in more efficient gene transfer and expression. Biochemical-based transfection methods are designed to minimize cytotoxicity and cell damage during the transfection process. Compared to physical methods such as electroporation, biochemical-based approaches typically result in higher cell viability and reduced cellular stress, making them ideal for sensitive cell types and applications.

Regional Insights

North America emerged as the dominant region in the Global Transfection Technologies Market in 2023. North America, particularly the United States, boasts a robust R&D infrastructure with leading academic institutions, research organizations, and biotechnology companies. The region's significant investment in biotechnology and life sciences research has fostered innovation and propelled advancements in transfection technologies. North America is home to many innovative companies and research institutions that are at the forefront of developing transfection technologies. These organizations continuously invest in research to improve existing transfection methods and develop novel approaches for efficient gene delivery. The demand for biopharmaceuticals, including recombinant proteins, monoclonal antibodies, and gene therapies, is high in North America. Transfection technologies play a crucial role in the production and development of these biologics, driving demand for advanced transfection methods and tools. The regulatory environment in North America, particularly in the United States, is conducive to the development and commercialization of biotechnological products and therapies. Regulatory agencies such as the Food and Drug Administration (FDA) provide clear guidelines for the approval and regulation of transfection technologies and related products.

Key Market Players

Promega Corporation

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Roche Molecular Systems, Inc.

QIAGEN NV

Inovio Pharmaceuticals

Mirus Bio LLC

Takara Bio Inc.

SignaGen Laboratories

MaxCyte, Inc.

Report Scope:

In this report, the Global Transfection Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transfection Technologies Market, By Transfection Method:

    Cotransfection Electroporation Cationic Lipid Transfection Lipofection Nucleofection In Vivo Transfection

Transfection Technologies Market, By Product:

    Reagent Instrument Others

Transfection Technologies Market, By Applications:

    Virus Production Protein Production Gene Silencing Stem Cell Reprogramming and Differentiation Stable Cell Line Generation Therapeutic Delivery Bio-Medical Research Others

Transfection Technologies Market, By Technology:

    Physical Transfection Biochemical Based Transfection Viral-Vector Based Transfection

Transfection Technologies Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transfection Technologies Market.

Available Customizations:

Global Transfection Technologies market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transfection Technologies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Transfection Method (Cotransfection, Electroporation, Cationic Lipid Transfection, Lipofection, Nucleofection, In Vivo Transfection)
    • 5.2.2. By Product (Reagent, Instrument, Others)
    • 5.2.3. By Applications (Virus Production, Protein Production, Gene Silencing, Stem Cell Reprogramming and Differentiation, Stable Cell Line Generation, Therapeutic Delivery, Bio-Medical Research, Protein Production, Others)
    • 5.2.4. By Technology (Physical Transfection, Biochemical Based Transfection, Viral-Vector Based Transfection)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America Transfection Technologies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Transfection Method
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By Technology
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Transfection Technologies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Transfection Method
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Technology
    • 6.3.2. Canada Transfection Technologies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Transfection Method
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Technology
    • 6.3.3. Mexico Transfection Technologies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Transfection Method
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Technology

7. Europe Transfection Technologies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Transfection Method
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By Technology
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Transfection Technologies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Transfection Method
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Technology
    • 7.3.2. United Kingdom Transfection Technologies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Transfection Method
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Technology
    • 7.3.3. Italy Transfection Technologies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Transfection Method
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Technology
    • 7.3.4. France Transfection Technologies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Transfection Method
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Technology
    • 7.3.5. Spain Transfection Technologies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Transfection Method
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Technology

8. Asia-Pacific Transfection Technologies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Transfection Method
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By Technology
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Transfection Technologies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Transfection Method
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Technology
    • 8.3.2. India Transfection Technologies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Transfection Method
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Technology
    • 8.3.3. Japan Transfection Technologies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Transfection Method
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Technology
    • 8.3.4. South Korea Transfection Technologies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Transfection Method
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Technology
    • 8.3.5. Australia Transfection Technologies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Transfection Method
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Technology

9. South America Transfection Technologies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Transfection Method
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By Technology
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Transfection Technologies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Transfection Method
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Technology
    • 9.3.2. Argentina Transfection Technologies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Transfection Method
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Technology
    • 9.3.3. Colombia Transfection Technologies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Transfection Method
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Technology

10. Middle East and Africa Transfection Technologies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Transfection Method
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By Technology
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Transfection Technologies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Transfection Method
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Technology
    • 10.3.2. Saudi Arabia Transfection Technologies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Transfection Method
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Technology
    • 10.3.3. UAE Transfection Technologies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Transfection Method
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Promega Corporation
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Bio-Rad Laboratories, Inc.
  • 14.4. Roche Molecular Systems, Inc.
  • 14.5. QIAGEN NV
  • 14.6. Inovio Pharmaceuticals
  • 14.7. Mirus Bio LLC
  • 14.8. Takara Bio Inc.
  • 14.9. SignaGen Laboratories
  • 14.10.MaxCyte, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer